Scorpius Strengthens National Defence with MCDC Membership
Scorpius joins MCDC to develop medical countermeasures for CBRN threats, enhancing biosecurity.
Scorpius Holdings, Inc. (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has announced its selection to join the Medical CBRN Defence Consortium (MCDC). The consortium, established by the U.S. Department of Defence in 2015, focuses on advancing medical countermeasures and technologies to protect military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats.
As a member of the MCDC, Scorpius will leverage its scientific expertise and resources to support the development of innovative solutions to address these threats. Jeff Wolf, CEO of Scorpius, expressed pride in the company’s selection, highlighting their dedication to developing therapies that protect public health and national security.
Joining the consortium will allow Scorpius to collaborate with government stakeholders, other companies, and academic institutions, as well as pursue funding for projects in line with the DoD’s medical defence objectives. This marks a key milestone in Scorpius’ efforts to contribute to U.S. biosecurity and national defence initiatives.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Bristol-Myers Squibb Gains FDA Accelerated Approval for Iberdomide in Relapsed or Refractory Multiple Myeloma
Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition
Discussion